OBJECTIVE
To assess the efficacy of glucomannan (GNN) as the sole treatment for abdominal pain-related functional gastrointestinal disorders (FGIDs).
METHODS
We conducted a double-blind, placebo-controlled, randomized trial. Patients were recruited among children referred to the Department of